Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Research & Development (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Research & Development readings, the most recent being $20000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 60.0% to $20000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $250000.0, a 18.57% decrease, with the full-year FY2025 number at $250000.0, down 18.57% from a year prior.
  • Research & Development hit $20000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $29000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.4 million in Q1 2021 to a low of $3000.0 in Q1 2024.
  • Median Research & Development over the past 5 years was $97000.0 (2024), compared with a mean of $452736.8.
  • Biggest five-year swings in Research & Development: tumbled 99.72% in 2023 and later skyrocketed 3033.33% in 2025.
  • Fennec Pharmaceuticals' Research & Development stood at $1.2 million in 2021, then tumbled by 90.58% to $117000.0 in 2022, then tumbled by 72.65% to $32000.0 in 2023, then soared by 56.25% to $50000.0 in 2024, then plummeted by 60.0% to $20000.0 in 2025.
  • The last three reported values for Research & Development were $20000.0 (Q4 2025), $29000.0 (Q3 2025), and $107000.0 (Q2 2025) per Business Quant data.